Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg
thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients
Phase:
Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Bamrasnaradura Infectious Diseases Institute Chulalongkorn University